Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.